1 / 7

Allergic Rhinitis Drug Market Opportunity, Resources, Shares And Size To 2021

Despite the rising prevalence of AR, and a large patient population that is dissatisfied with the current treatment options, the market size for symptomatic therapies alone is set to shrink, as the remaining branded products lose patent protection.

john999
Download Presentation

Allergic Rhinitis Drug Market Opportunity, Resources, Shares And Size To 2021

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Allergic Rhinitis Drug Market Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast To 2024 Summary Allergic Rhinitis (AR) is becoming an increasingly prevalent condition, with the most common form being moderate to severe in nature (Baena-Cagnani et al., 2015). According to the European Academy of Allergy and Clinical Immunology (EAACI), 50% of Europeans will suffer from an allergy by 2027 (Papadopoulos et al., 2012). The allergic rhinitis (AR) market has declined very slowly over the past decade, as has it become saturated with relatively efficacious standard therapies, such as antihistamines (AHs), intranasal corticosteroids (INCS), and leukotriene receptor antagonists (LRAs), and has also been facing increasing generic competition. Despite the rising prevalence of AR, and a large patient population that is dissatisfied with the current treatment options, the market size for symptomatic therapies alone is set to shrink, as the remaining branded products lose patent protection. There is an increasing shift in the transfer of prescription AR products to over-the-counter (OTC) status, which is driving patients to pharmacies rather than to physicians, further diluting the prescription AR market. The immense, crowded generic AR market has been largely unappealing to drug manufacturers. Consequently, only two symptomatic therapies are expected to launch before 2024. Highlights Key Questions Answered - Allergic Rhinitis symptoms can be controlled in the majority of patients using the current standard therapies. Nevertheless, in around 20% of people with allergic rhinitis, the disease remains symptomatic and inadequately controlled. Therefore, there are considerably high unmet needs within the indication. What are the main unmet needs in this market? Detailed report at: http://www.radiantinsights.com/research/pharmapoint-allergic-rhinitis- global-drug-forecast-and-market-analysis-to-2024 - The current late-stage allergic rhinitis pipeline is sparse. Will the late-stage symptomatic drugs make a significant impact on the allergic rhinitis market? What strategies are drug developers undertaking to penetrate this difficult but potentially very lucrative market? How will immunotherapies affect the market landscape? - The prevalence of environmental diseases, including allergic rhinitis, is increasing worldwide, with an estimated 46 million US citizens are likely to suffer from allergic rhinitis in 2024. How will epidemiological changes impact the growth of the future market? Key Findings

  2. - The main driver of growth in the AR market will be the introduction of several AIT tablets: Merck's Grastek (grass), Ragwitek (ragweed), and Mitizax (house dust mite [HDM]) tablets, as well as Greer's Oralair (grass) in the US. These new products overcome the inconvenience of conventional subcutaneous immunotherapies (SCITs). - The major global barrier for the AR market will be the increasing push for patients to self- medicate using OTC drugs will decrease the prescription AR drug market size. - There is little room for new entrants, as the market is well-served by a wealth of symptomatic therapies. Since the competition is increasing, the market for AR therapies is becoming increasingly less lucrative. Also, there are currently no breakthrough symptomatic therapy products in clinical development. - The remaining clinical unmet needs in this market include the requirement for more efficacious products, and the underserved area of causative therapies, such as immunotherapies, which target the underlying cause of the disease. Scope - Overview of AR, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines. - Annualized AR therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2014 and forecast for ten years to 2024. Browse All Reports of This Category @ http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare - Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the AR therapeutics market. - Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs. - Analysis of the current and future market competition in the global AR therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. Reasons to buy - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list. - Develop business strategies by understanding the trends shaping and driving the global AR therapeutics market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AR therapeutics market in future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

  3. - Track drug sales in the global AR therapeutics market from 2014-2024. - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. Table Of Content: 1.1 List of Tables 18 1.2 List of Figures 21 2 Introduction 22 2.1 Catalyst 22 2.2 Related Reports 23 2.3 Upcoming Related Reports 23 3 Disease Overview 24 3.1 Etiology and Pathophysiology 24 3.2 Symptoms 27 3.3 Classification 28 3.3.1 Seasonal and Perennial AR 28 3.3.2 ARIA Classification of AR 28 3.4 Diagnosis 29 3.5 Quality of Life 31 Request Free Sample Of This Study @ http://www.radiantinsights.com/research/pharmapoint-allergic-rhinitis-global-drug- forecast-and-market-analysis-to-2024#tabs-4 4 Epidemiology 32 4.1 Disease Background 32 4.2 Risk Factors and Comorbidities 33 4.2.1 A family history of AR is a strong predictor for AR in children and adults 34 4.2.2 Exposure to allergens in the environment increases the risk for AR 35 4.2.3 Urban living elevates the risk for AR 35 4.2.4 Comorbidities 36 4.3 Global and Historical Trends 38 4.3.1 US 38 4.3.2 5EU 39 4.3.3 Japan 40 4.4 Forecast Methodology 41 4.4.1 Sources Used 43 4.4.2 Sources Not Used 46 4.4.3 Forecast Assumptions and Methods 46 4.5 Epidemiological Forecast for AR (2013-2023) 49 4.5.1 Total Prevalent Cases of AR 49 4.5.2 Age-Specific Total Prevalent Cases of AR 51

  4. 4.5.3 Sex-Specific Total Prevalent Cases of AR 53 4.5.4 Age-Standardized Total Prevalence of AR 55 4.5.5 Distribution of Total Prevalent Cases of AR by Severity 57 4.5.6 Distribution of Total Prevalent Cases of AR by Type 58 4.5.7 Distribution of Total Prevalent Cases of AR Sensitized to Specific Allergens 59 4.6 Discussion 60 4.6.1 Epidemiological Forecast Insight 60 4.6.2 Limitations of the Analysis 60 4.6.3 Strengths of the Analysis 61 5 Disease Management 62 5.1 Diagnosis and Treatment Overview 62 5.1.1 Diagnosis 62 5.1.2 Treatment Guidelines and Leading Prescribed Drugs 63 5.1.3 Clinical Practice 66 5.2 US 75 5.3 France 78 5.4 Germany 80 5.5 Italy 84 5.6 Spain 86 5.7 UK 88 5.8 Japan 90 Complete report is available at: http://www.radiantinsights.com/research/pharmapoint- allergic-rhinitis-global-drug-forecast-and-market-analysis-to-2024 6 Competitive Assessment 93 6.1 Overview 93 6.2 Oral H1 Antihistamines 97 6.2.1 Overview 97 6.2.2 Efficacy 106 6.2.3 Safety 107 6.2.4 SWOT Analysis 109 6.2.5 Forecast 110 6.3 Intranasal Antihistamines 110 6.4 Intranasal Corticosteroids 113 6.4.1 Overview 113 6.4.2 Efficacy 120 6.4.3 Safety 122 6.4.4 SWOT Analysis 123 6.4.5 Forecast 124 6.5 Combination Intranasal Corticosteroids/Antihistamines 124 6.5.1 Dymista 124 6.6 Decongestants 133 6.6.1 Overview 133

  5. 6.7 Intranasal Anticholinergics 136 6.7.1 Overview 136 6.8 Leukotriene Receptor Antagonists 137 6.8.1 Overview 137 6.9 Cromones 140 6.9.1 Overview 140 6.10 Thromboxane A2 Receptor Antagonists 141 6.10.1 Overview 141 6.11 TH2 Cytokine Inhibitors 142 6.11.1 Overview 142 7 Unmet Need and Opportunity 143 7.1 Overview 143 7.2 Pharmacist Education 145 7.2.1 Unmet Need 145 7.2.2 Gap Analysis 147 7.2.3 Opportunity 148 7.3 Patient Compliance With Intranasal Corticosteroids and Antihistamines 150 7.3.1 Unmet Need 150 7.3.2 Gap Analysis 151 7.3.3 Opportunity 153 7.4 More Convenient and More Patient-Friendly Immunotherapies 156 7.4.1 Unmet Need 156 7.4.2 Gap Analysis 157 7.4.3 Opportunity 159 7.5 Primary Care Physician Education 160 7.5.1 Unmet Need 160 7.5.2 Gap Analysis 162 7.5.3 Opportunity 163 To Get Sample Copy of Report visit @ http://www.radiantinsights.com/research/pharmapoint-allergic-rhinitis-global-drug- forecast-and-market-analysis-to-2024#tabs-4 8 Pipeline Assessment 165 8.1 Promising Drugs in Clinical Development 166 8.1.1 S-555739 166 8.1.2 HP-3060 172 9 Current and Future Players 177 9.1 Overview 177 9.2 Trends in Corporate Strategy 179 9.3 Major Companies 180 9.3.1 Merck & Co. 180 9.3.2 GlaxoSmithKline 184

  6. 9.3.3 Sumitomo Dainippon Pharma 186 9.3.4 Sanofi 188 9.3.5 Teva 191 9.3.6 Meda AB 192 10 Market Outlook 195 10.1 Global Markets 195 10.1.1 Forecast 195 10.1.2 Drivers and Barriers - Global Issues 200 10.2 United States 205 10.2.1 Forecast 205 10.2.2 Key Events 210 10.2.3 Drivers and Barriers 210 10.3 5EU 212 10.3.1 Forecast 212 10.3.2 Key Events 217 10.3.3 Drivers and Barriers 217 10.4 Japan 225 10.4.1 Forecast 225 10.4.2 Key Events 230 10.4.3 Drivers and Barriers 230 11 Appendix 234 11.1 Bibliography 234 11.2 Abbreviations 247 11.3 Methodology 252 About Us Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of Ancillary services such as, research partnerships/ tie-ups and customized research solutions. Media Contact: Michelle Thoras Corporate Sales Specialist, USA Radiant Insights, Inc Phone: 1-415-349-0054 Toll Free: 1-888-202-9519 Email: sales@radiantinsights.com Website: Radiant Insights Visit Our Blog: radiantri.blogspot.com

More Related